Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P24666

UPID:
PPAC_HUMAN

ALTERNATIVE NAMES:
Adipocyte acid phosphatase; Low molecular weight cytosolic acid phosphatase; Red cell acid phosphatase 1

ALTERNATIVE UPACC:
P24666; A8K1L9; B5MCC7; P24667; Q16035; Q16036; Q16725; Q3KQX8; Q53RU0

BACKGROUND:
Low molecular weight phosphotyrosine protein phosphatase, with alternative names such as Adipocyte acid phosphatase and Red cell acid phosphatase 1, operates on tyrosine phosphorylated proteins and different acyl phosphates. The enzyme exhibits unique substrate preferences between its isoform 1 and isoform 2, despite not possessing phosphatase activity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Low molecular weight phosphotyrosine protein phosphatase may pave the way for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.